Enfusion Cash from 2010 to 2024

ENFN Stock  USD 8.80  0.36  3.93%   
Enfusion Cash yearly trend continues to be very stable with very little volatility. Cash is likely to grow to about 40.1 M this year. Cash is the total amount of money in the form of currency that Enfusion has in its possession. This includes all bills, coins, and funds in bank accounts. View All Fundamentals
 
Cash  
First Reported
2010-12-31
Previous Quarter
35.6 M
Current Value
40.1 M
Quarterly Volatility
21.4 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Enfusion financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enfusion's main balance sheet or income statement drivers, such as Tax Provision of 867 K, Net Interest Income of 1.7 M or Depreciation And Amortization of 4.7 M, as well as many indicators such as Price To Sales Ratio of 4.66, Dividend Yield of 0.0034 or PTB Ratio of 16.74. Enfusion financial statements analysis is a perfect complement when working with Enfusion Valuation or Volatility modules.
  
Check out the analysis of Enfusion Correlation against competitors.
To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.

Latest Enfusion's Cash Growth Pattern

Below is the plot of the Cash of Enfusion over the last few years. Cash refers to the most liquid asset of Enfusion, which is listed under current asset account on Enfusion balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Enfusion customers. The amounts must be unrestricted with restricted cash listed in a different Enfusion account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. Enfusion's Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Enfusion's overall financial position and show how it may be relating to other accounts over time.
Cash10 Years Trend
Slightly volatile
   Cash   
       Timeline  

Enfusion Cash Regression Statistics

Arithmetic Mean18,369,933
Geometric Mean10,983,174
Coefficient Of Variation116.50
Mean Deviation17,220,169
Median5,898,000
Standard Deviation21,401,041
Sample Variance458T
Range58.5M
R-Value0.72
Mean Square Error240.6T
R-Squared0.51
Significance0
Slope3,424,971
Total Sum of Squares6412.1T

Enfusion Cash History

202440.1 M
202335.6 M
202262.5 M
202164.4 M
202013.9 M

Other Fundumenentals of Enfusion

Enfusion Cash component correlations

About Enfusion Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Enfusion income statement, its balance sheet, and the statement of cash flows. Enfusion investors use historical funamental indicators, such as Enfusion's Cash, to determine how well the company is positioned to perform in the future. Although Enfusion investors may use each financial statement separately, they are all related. The changes in Enfusion's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Enfusion's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Enfusion Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Enfusion. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash35.6 M40.1 M
Cash And Short Term Investments35.6 M40.1 M
Change In Cash-26.9 M-25.6 M
Free Cash Flow14.8 M15.6 M
Begin Period Cash Flow62.5 M33.5 M
Total Cashflows From Investing Activities-7.1 M-7.5 M
Other Cashflows From Financing Activities-59.3 M-56.3 M
Other Non Cash Items8.2 M8.6 M
Total Cash From Operating Activities24.5 M25.7 M
Total Cash From Financing Activities-41.9 M-39.8 M
End Period Cash Flow35.6 M40.1 M
Cash And Cash Equivalents Changes-1.6 M-1.6 M
Cash Flows Other Operating-1.4 M-1.4 M
Free Cash Flow Yield 0.02  0.02 
Operating Cash Flow Per Share 0.28  0.29 
Free Cash Flow Per Share 0.17  0.18 
Cash Per Share 0.40  0.37 
Capex To Operating Cash Flow(0.40)(0.38)
EV To Operating Cash Flow 34.12  35.83 
EV To Free Cash Flow 56.40  59.22 
Price To Operating Cash Flows Ratio 34.95  36.69 
Price To Free Cash Flows Ratio 57.76  60.65 
Cash Ratio 1.75  2.46 
Cash Conversion Cycle 44.69  42.54 
Operating Cash Flow Sales Ratio 0.14  0.10 
Free Cash Flow Operating Cash Flow Ratio 0.60  0.57 
Cash Flow Coverage Ratios 1.59  0.82 
Price Cash Flow Ratio 34.95  36.69 
Cash Flow To Debt Ratio 1.59  0.82 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Additional Information and Resources on Investing in Enfusion Stock

When determining whether Enfusion offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enfusion's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enfusion Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enfusion Stock:
Check out the analysis of Enfusion Correlation against competitors.
To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enfusion. If investors know Enfusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enfusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.94)
Earnings Share
0.02
Revenue Per Share
2.055
Quarterly Revenue Growth
0.173
Return On Assets
0.0331
The market value of Enfusion is measured differently than its book value, which is the value of Enfusion that is recorded on the company's balance sheet. Investors also form their own opinion of Enfusion's value that differs from its market value or its book value, called intrinsic value, which is Enfusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enfusion's market value can be influenced by many factors that don't directly affect Enfusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enfusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Enfusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enfusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.